Use of levosimendan, a new inodilator, for postoperative myocardial stunning in a premature neonate

Lechner, Evelyn; Moosbauer, W.; Pinter, Miklos; Mair, Rudolf; Tulzer, Gerald

doi:10.1097/01.pcc.0000253026.67341.5d

Cited by 44 publications

(32 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Low grade evidence data exists in the form of a case report about its use in preterm population with improvement in LVO post-cardiac surgery [64].…”

Section: Discussionmentioning

confidence: 99%

Cardiovascular Drug Therapy for Human Newborn: Review of Pharmacodynamic Data

Ergenekon

Rojas-Anaya

Bravo

et al. 2018

CPD

View full text Add to dashboard Cite

Background: Circulatory failure in preterm and term newborn infants is commonly treated with inotropes or vasoactive medications. In this structured literature review the available data on pharmacodynamic effects of the inotropes adrenaline, dobutamine, dopamine, levosimendan, milrinone, noradrenaline, and the vasoactive drugs vasopressin and hydrocortisone are presented. Methods: Structured searches were conducted to identify relevant articles according to pre-defined inclusion criteria which were human clinical trials published after 2000.Results: Out of 101 identified eligible studies only 22 studies met the criteria for evidence based practice guidelines level I to IV. The most prevalent pharmacodynamic effects were increase in blood pressure and/or heart rate, which were also the most frequently studied circulatory parameters. Conclusion: This review demonstrates the need for further systematic studies on all reviewed drugs with incorporation of novel noninvasive biomarkers in this vulnerable patient group, for more timely and appropriate treatment for clinical efficacy.

show abstract

“…Low grade evidence data exists in the form of a case report about its use in preterm population with improvement in LVO post-cardiac surgery [64].…”

Section: Discussionmentioning

confidence: 99%

Cardiovascular Drug Therapy for Human Newborn: Review of Pharmacodynamic Data

Ergenekon

Rojas-Anaya

Bravo

et al. 2018

CPD

View full text Add to dashboard Cite

show abstract

“…As opening of myocardial K ATP channels plays a key role in the mediation of ischemic preconditioning, one may speculate that administration of the K ATP channel opener levosimendanbefore ischemia may also prevent or attenuate the negative effects of myocardial stunning. recent small studies have repeatedly demonstrated ap ossible valuable role of levosimendan in the frequently observed setting of myocardial stunning (12)(13)(14).…”

Section: Myocardial Stunningmentioning

confidence: 99%

Medical Support and Surgery of the Failing Heart: Levosimendan

Toller

Knez

2007

Scand J Surg

View full text Add to dashboard Cite

“…In several studies, levosimendan was found to increase the heart contraction force and stroke volume of patients with myocardial stunning [3,4,5,6]. The goal of this study was to evaluate the efficacy of levosimendan for treating myocardial stunning after emergency PCI in patients with AMI.…”

Section: Introductionmentioning

confidence: 99%

Enhancement of Myocardial Function and Reduction of Injury with Levosimendan after Percutaneous Coronary Intervention for Acute Myocardial Infarction: A Pilot Study

Yan

et al. 2014

Cardiology

View full text Add to dashboard Cite

Objectives: To determine the short-term clinical effects of levosimendan in acute myocardial infarction (AMI) patients with myocardial stunning after emergency percutaneous coronary intervention (PCI). Methods: The study population consisted of 30 patients with AMI who received emergency PCI and satisfied the inclusion criteria. Levosimendan was given as a continuous infusion of 0.1 μg/kg/min for 24 h, and the remaining 10 patients received placebo treatment. The patients were observed with invasive haemodynamic monitoring and were evaluated biochemically and echocardiographically before and after the drug infusion. Results: Following treatment, biochemical indices (not including creatine kinase and its MB fraction) were significantly lower in the levosimendan group than in the placebo group. Meanwhile, left-ventricular (LV) end-systolic volume, mean pulmonary arterial pressure, pulmonary capillary wedge pressure and systemic vascular resistance were significantly reduced in the levosimendan group, whereas the early-to-late diastolic velocities ratio, LV ejection fraction, cardiac index and cardiac power index were increased. Troponin I levels were reduced and fewer stunned and infarction segments were observed in the patients treated with levosimendan. Conclusions: Levosimendan can significantly improve the myocardium function of patients with myocardial stunning after PCI.

show abstract

Use of levosimendan, a new inodilator, for postoperative myocardial stunning in a premature neonate

Abstract: In this premature neonate with postoperative low cardiac output syndrome due to failing myocardial function, levosimendan was a potent inotropic agent.

Cited by 44 publications

References 10 publications

Cardiovascular Drug Therapy for Human Newborn: Review of Pharmacodynamic Data

Cardiovascular Drug Therapy for Human Newborn: Review of Pharmacodynamic Data

Medical Support and Surgery of the Failing Heart: Levosimendan

Enhancement of Myocardial Function and Reduction of Injury with Levosimendan after Percutaneous Coronary Intervention for Acute Myocardial Infarction: A Pilot Study

Contact Info

Product

Resources

About